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Abstract In recent years, it has become evident that heart
failure is not solely due to reduced contractile performance
of the heart muscle as impaired relaxation is evident in
almost all heart failure patients. In more than half of all
heart failure patients, diastolic dysfunction is the major
cardiac deficit. These heart failure patients have normal (or
preserved) left ventricular ejection fraction, but impaired
diastolic function evident from increased left ventricular
end-diastolic pressure. Perturbations at the cellular level
which cause impaired relaxation of the heart muscle
involve changes in Ca2+-handling proteins, extracellular
matrix components, and myofilament properties. The
present review discusses the deficits in myofilament
function observed in human heart failure and the most
likely underlying causal protein changes. Moreover, the
consequences of impaired myofilament function for in vivo
diastolic dysfunction are discussed taking into account the
reported changes in Ca2+ handling.
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Systolic and diastolic function of the heart:
role of the myofilaments
Every heart beat, the ventricles eject blood into the small
and large circulation to provide organs with sufficient
oxygen. Cardiac output depends on the amount of blood
ejected per heart beat (i.e., stroke volume) and heart rate.
Although myocardial muscle contraction is indispensible
for proper cardiac output during the systolic (activation)
phase of the cardiac cycle, filling of the ventricles during
the diastolic (relaxation) phase heavily depends on proper
cardiac muscle relaxation. The latter is even more important
during increased cardiac stress as occurs during exercise.
To match cardiac output to increased demands of the body,
heart rate is increased by enhanced sympathetic drive. The
magnitude of contraction is increased by increased Ca2+-
induced Ca2+-release from the sarcoplasmic reticulum (SR)
within the heart muscle cells. To match the increase in heart
rate, a faster relaxation of the heart muscle is required
which is achieved by increased re-uptake of Ca2+ into the
SR and desensitization of the myofilaments to Ca2+ [6, 56].
Upon depolarization of the heart muscle cells, L-type
Ca2+-channels are opened, which causes Ca2+ entry into the
cytosol and triggers Ca2+ release from the SR via the
ryanodine receptors (RyR2; so-called Ca2+-induced Ca2+-
release). Subsequently, Ca2+ binds to troponin C and
initiates myofilament contraction via interactions between
the thick filament myosin heads and the thin filament
component actin. Relaxation of the heart muscle cells
occurs upon detachment of Ca2+ from the troponin complex
and subsequent re-uptake of Ca2+ into the SR via the SR
Ca2+-ATPase (SERCA2), which activity depends on the
phosphorylation status of phospholamban (i.e., unphos-
phorylated phospholamban blocks SERCA2 activity).
SERCA2 is responsible for re-uptake of ~70% of the Ca2+
involved in the Ca2+ transient and approximately 30% of
the cytosolic Ca2+ is removed out of the cell via the Na+–
Ca2+ exchanger (NCX) [6, 7]. Changes in cellular Ca2+
cycling and myofilament properties are under the tight
control of kinases and phosphatases within the heart muscle
cells, which respectively phosphorylate and dephosphory-
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late cellular target proteins that regulate contraction and
relaxation [29, 51]. Upon increased sympathetic activation,
β1-adrenergic receptors are activated which initiates protein
kinase A (PKA)-mediated phosphorylation of proteins
involved in Ca2+ handling (RyR2, phospholamban) and of
the myofilament target proteins troponin I (cTnI), myosin
binding protein C (cMyBP-C), and titin [6, 28, 40, 56, 75].
The predominant role of the myofilaments during increased
β1-adrenergic receptor stimulation is enhancement of
relaxation, which is caused by desensitization of the
myofilaments to Ca2+ (Fig. 1a) and faster kinetics of
cross-bridge cycling [17, 77]. The PKA-mediated phos-
phorylation of cTnI is thought to be the major contributor to
myofilament Ca2+-desensitization [56]. More recent studies
have indicated a modulating role for cMyBP-C in the PKA-
mediated reduction of myofilament Ca2+-sensitivity [16, 17,
37], although the major effect exerted by phosphorylated
cMyBP-C seems to be enhancement of the rate of
contraction and relaxation [39, 44, 58, 59]. The third
protein phosphorylated upon β1-adrenergic receptor activa-
tion is the giant protein titin [75], which, upon PKA-
mediated phosphorylation, reduces passive stiffness of
cardiac muscle cells [11, 40, 75]. Overall, the PKA-
mediated enhancement of myofilament relaxation is critical
to maintain proper cardiac performance at increased heart
rates associated with β-adrenergic stimulation.
Apart from phosphorylation-induced changes in myofil-
ament function, a change in sarcomere length upon
increased filling of the ventricles during diastole increases
the maximal force-generating capacity and the Ca2+-
sensitivity of the myofilaments (Fig. 1b). This length-
dependent activation is called the Frank–Starling mecha-
nism of the heart and underlies increased cardiac output at
increased left ventricular (LV) end-diastolic volumes. The
exact mechanisms underlying the increased force-
generating capacity of the myofilaments at higher sarco-
mere lengths are still controversial and have been exten-
sively discussed in previous reviews [33, 36].
Lastly, changes in heart rate adjust myofilament proper-
ties to cardiac pump performance [2, 42, 43, 69]. Under
physiological conditions, an increase in cardiac stimulation
frequency results in enhanced systolic function (so-called
positive force–frequency relation), which has been
attributed to an increased Ca2+ influx into the cardiomyo-
cytes. The increase in Ca2+ influx increases SR Ca2+
content and promotes the Ca2+-induced Ca2+-release.
Varian and Janssen [69] observed a decrease in myofila-
ment Ca2+-sensitivity with increased frequency in the
healthy myocardium and suggested that, similar to β-
adrenergic PKA-mediated Ca2+-desensitization, the
frequency-induced myofilament Ca2+-desensitization
accelerates relaxation of the heart muscle. The
frequency-mediated alteration in myofilament Ca2+-sensi-
tivity most likely involves changes in protein phosphory-
lation caused by Ca2+-activated kinases [42, 61, 70].
Systolic and diastolic heart failure
The amount of blood ejected as a fraction of total blood in
the ventricles at the end of the diastolic phase is called the
ejection fraction. In clinical practice, LV ejection fraction
(LVEF) is used as a measure to define systolic cardiac
performance. A patient with a LV ejection fraction <45%
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Fig. 1 Myofilament responses to increased sympathetic activation
and increased left ventricular filling during diastole (Frank–Starling
mechanism). a Activation of protein kinase A (PKA) upon β-
adrenergic receptor stimulation increases phosphorylation of myofil-
ament proteins (troponin I, myosin binding protein C and titin) and
thereby reduces myofilament Ca2+-sensitivity (indicated by the white
arrow), enhances cross-bridge kinetics and lowers passive stiffness.
The PKA-mediated changes in myofilament properties contribute to
enhanced muscle relaxation, which is required for proper filling of the
heart during diastole. b An increase in left ventricular filling
(increased end-diastolic left ventricular volume) increases the maximal
force-generating capacity (black arrow) and myofilament Ca2+-
sensitivity (white arrow) and underlies increased cardiac output during
the subsequent systolic phase
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has heart failure with reduced ejection fraction (HFREF)
or systolic heart failure. Over the last two decades, it
became evident that more than 50% of all heart failure
patients suffer of heart failure with normal (or preserved)
ejection fraction (HFNEF) [53]. Compared to HFREF
patients, these so-called HFNEF patients have a higher
mortality and morbidity [1, 8]. The main perturbation in
HFNEF patients is diastolic dysfunction. Moreover,
frequently, patients with systolic dysfunction also show
impaired diastolic function. The epidemiologic evidence
that diastolic rather that systolic dysfunction is a major
cause of cardiac failure in Western society has triggered
scientists to investigate the underlying mechanisms of
diastolic dysfunction in humans.
Perturbations at the cellular level which are thought to
underlie diastolic dysfunction in human heart failure are:
impaired Ca2+-handling [7], extracellular matrix modifica-
tions [11, 63], and myofilament dysfunction [29, 30, 67,
73]. In heart failure, the decline in the cytosolic Ca2+-
transient is slowed, which is most likely caused by reduced
re-uptake of Ca2+ into the SR due to reduced SERCA2
expression and reduced PKA-mediated phosphorylation of
phospholamban. The reduced Ca2+-transient decline con-
tributes to diastolic dysfunction and hampers ventricular
filling during the relaxation phase of the heart. The reduced
Ca2+ re-uptake also lowers SR Ca2+ content and thereby
reduces the amount of Ca2+ available for the subsequent
contraction. Thus, perturbations in Ca2+ handling contribute
to both systolic and diastolic dysfunction of the heart.
Cardiac dysfunction has been ascribed to alterations in the
extracellular matrix. Stiffness of the extracellular matrix is
largely determined by collagen through regulation of its
total amount, the relative abundance of collagen type I and
the degree of collagen cross-linking. Excessive collagen
type I deposition results from an imbalance between an
exaggerated synthesis and a depressed degradation. Com-
parison of myocardial structure of LV endomyocardial
catheter biopsies from HFNEF and HFREF patients showed
similar increases in collagen volume fraction in both groups
(respectively, 12.2±1.4% and 14.4±1.5%) compared to
normal values (5.4±2.2%)[63]. In the HFREF group,
collagen deposition was significantly enhanced by diabetes
mellitus and associated with increased deposition of AGEs
(advanced glycation end products) [64]. AGEs result from
long-standing hyperglycemia and augment passive stiffness
via cross-linking and enhanced collagen formation. Recent-
ly, Westermann et al. [72] provided evidence that enhanced
deposition and remodelling of the extracellular matrix in
HFNEF patients may involve myocardial inflammation. In
addition to collagen deposition, intrinsic cardiomyocyte
stiffness contributes to LV diastolic dysfunction evident
from the high myofilament passive force observed in
patients with HFNEF and HFREF [63].
Diastolic heart failure: role of the myofilaments
The first studies on myofilament function in membrane-
permeabilized single cell preparations were already
performed more than 30 years ago [22, 26]. Myofilament
function is commonly measured in Triton-permeabilized
cardiac muscle preparations, which allows investigation of
myofilament properties without interference of extracellu-
lar matrix components and under well-controlled condi-
tions (e.g., fixed sarcomere length and calcium
concentration) [65]. Nowadays, single cells can be isolated
from small needle biopsies, which are obtained during
cardiac surgery or cardiac catheterization [11, 18]. The
major limitation of the method may be the small size of
the human cardiac tissue samples available for research, as
throughout the heart, regional and transmural differences
may exist in myofilament properties. Heterogeneity in
myofilament function and protein phosphorylation may be
larger in cardiac disease as the disease trigger may be
localized to a certain area of the heart. Transmural
differences in myofilament properties have been reported
in rodent studies [15, 21]. To assess regional differences in
myofilament properties in the human heart, LV subepi-
and subendocardial biopsies were obtained during valve
replacement surgery from patients with mitral valve or
aortic valve stenosis or insufficiency [66]. In the latter
study, we did not find evidence for regional differences in
myofilament function and protein composition within the
human ventricle. In addition, recent analysis of variability
of the phosphorylation of the PKA target proteins cTnI
and cMyBP-C showed that the intra-patient variability in
protein phosphorylation was comparable between donor
and cardiomyopathy samples [62]. Thus, our data indicate
that within the precision of the measurements small,
biopsy-sized cardiac human tissue samples are represen-
tative for the region of the free LV wall from which they
are obtained.
The initial studies in humans were done in samples
obtained during heart transplantation surgery from end-
stage failing patients with idiopathic (IDCM) or ischemic
(ISHD) cardiac disease [67, 73]. A comparison was made
with cells isolated from non-failing donor hearts. Myo-
filament Ca2+-sensitivity was increased in end-stage
failing compared to donor hearts as illustrated in Fig. 2a.
The higher sensitivity for Ca2+ in end-stage failing hearts
may exert a beneficial effect on systolic cardiac perfor-
mance, but it may limit relaxation during diastole.
Diastolic function may be further impaired by the
combined changes in myofilament properties and pertur-
bations in Ca2+ handling as discussed above. The blunted
decline in Ca2+-transient decay in failing myocardium will
increase diastolic Ca2+ levels and exaggerate diastolic
dysfunction as shown in Fig. 2b.
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The enhanced myofilament Ca2+-sensitivity has been
ascribed to defects in the β-adrenergic receptor pathway as
reduced phosphorylation of the PKA target proteins, cTnI
and cMyBP-C, has been reported in end-stage failing
compared to non-failing donor myocardium [9, 20, 25,
48, 67]. In further support for defective β-adrenergic
signaling was the observation that myofilament Ca2+-
sensitivity was normalized to donor values after treatment
of cells with exogenous PKA [67]. Enhanced myofilament
Ca2+-sensitivity and correction to control values with PKA
treatment have been observed in different animal models as
well (e.g., post myocardial infarction or pressure overload)
[23, 30, 68]. However, in all animal models, it has been
difficult to find proof for reduced PKA-mediated phos-
phorylation of cTnI and cMyBP-C [30]. Only recently, we
have observed a blunted cTnI phosphorylation at the PKA
sites (Serines 23/24) upon dobutamine infusion in post-
infarction compared to sham pigs [10]. In contrast, the
dobutamine-induced phosphorylation of cMyBP-C at
Ser282 (one of the PKA sites) was preserved in post-
infarction hearts, and coincided with increased autophos-
phorylation of the cytosolic Ca2+-dependent calmodulin
kinase II (CaMKII-δC) [10]. The exact cause of the
enhanced myofilament Ca2+-sensitivity in cardiac disease
models needs to be further investigated and requires
analysis of site-specific protein phosphorylation using mass
spectrometry as in addition to reduced PKA activity
changes in other kinase (protein kinase C, CaMKII) and
in phosphatases have been documented in cardiac disease
development [4, 5, 13, 51]. In a recent study [32], we have
observed that alterations in the β-adrenergic receptor
pathway are more pronounced in human IDCM than in
ISHD and may reflect sequential changes in cellular protein
composition and function and indicates the need to evaluate
changes in myofilament properties in the acute phase after
the initial disease trigger (e.g., infarction, valve rupture) and
at later stages during remodelling of the heart muscle.
The increased myofilament Ca2+-sensitivity reported in
end-stage human heart failure is not a consistent observa-
tion in different experimental models of heart failure.
Similar to humans, an increased myofilament Ca2+-sensi-
tivity has been observed in pig and mice with a myocardial
infarction [10, 23], while a reduction in Ca2+-sensitivity
was found in rat models with congestive heart failure due to
pressure overload or myocardial infarction [4, 5]. The
direction of the Ca2+-sensitivity shift may involve the stage
of cardiac disease (i.e., period after the initial cardiac
insult). Possible explanations for the opposite changes in
myofilament Ca2+-sensitivity in cardiac disease models
have been discussed in recent papers [30, 47, 57].
Apart from reduced PKA-mediated protein phosphory-
lation other myofilament protein modifications have been
reported which may underlie impaired diastolic function of
the heart. Varian et al. [70] reported a lack of frequency-
dependent Ca2+-desensitization in a rabbit model of
pressure overload, which was attributed to lack of
frequency-dependent cTnI phosphorylation. A reduction in
myosin light chain 2 (MLC-2) phosphorylation has been
reported in human end-stage heart failure [67], while loss of
a transmural MLC-2 phosphorylation gradient has been
described in rodent models [15, 21]. Phosphorylation of
MLC-2 has been shown to enhance cross-bridge kinetics
and force production per unit Ca2+ [55], while ablation of
MLC-2 phosphorylation in mice resulted in a blunted
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Fig. 2 a Force measurements in single Triton-permeabilized cardio-
myocytes from end-stage failing patients with ischemic and idiopathic
cardiomyopathy showed increased myofilament Ca2+-sensitivity com-
pared to non-failing donor hearts [67]. Translation of the altered
responsiveness to Ca2+ to cardiac pump function suggests that the
force-generating capacity of myofilaments will be higher at systolic
[Ca2+] and improves cardiac output, while the enhanced myofilament
Ca2+-sensitivity may impair relaxation of the heart muscle during
diastole. b Taking into account the reported changes in the Ca2+
transient in human heart failure (i.e. reduced systolic peak Ca2+ and
slowed diastolic Ca2+ decline [7]) would further worsen diastolic
function. The combination of enhanced myofilament Ca2+-sensitivity
and increased diastolic Ca2+ levels is illustrated in b
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response to β-adrenergic receptor stimulation [54]. Specific
and selective proteolysis of cTnI at its C-terminus has been
proposed to play a key role in human myocardial ischemic
disease, including stunning [27, 52]. The C-terminally
truncated cTnI protein has been reported to reduce the
force-generating capacity upon ischemia-reperfusion in
rodent studies. Incorporation of C-terminal truncated cTnI
in rat cardiac muscle depressed maximal force and
increased cross-bridge kinetics [60]. However, exchange
of C-terminal truncated cTnI in human cardiomyocytes had
no effect on maximal force development and increased Ca2
+-sensitivity of the myofilaments [49]. This indicates that
cTnI truncation at the C-terminus in human cardiomyocytes
impairs diastolic rather than systolic function. In contrast,
truncation of cTnI at the N-terminus has been shown to
enhance ventricular diastolic function [3, 76].
Apart from the increased myofilament responsiveness to
Ca2+ in end-stage failing human hearts, studies in cardio-
myocytes isolated from cardiac catheter biopsies from
HFNEF patients revealed significantly elevated passive
stiffness compared to control cells (Fig. 3a) [11, 63]. The
unique advantage of the catheter biopsies is that in vivo
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Fig. 3 a Isolation of single
Triton-permeabilized cardio-
myocytes from biopsies taken
during cardiac catheterization
from patients with a diastolic
dysfunction evident from in-
creased left ventricular (LV)
end-diastolic pressures
(>16 mmHg: heart failure
patients with normal (or pre-
served) LV ejection fraction,
HFNEF) revealed increased
passive stiffness compared to
control cells from patients with
normal LV ejection fraction and
normal LV end-diastolic pres-
sure [11]. The high passive
stiffness was corrected to control
values upon treatment with pro-
tein kinase A (PKA), suggesting
that the high passive force is
largely caused by hypophos-
phorylation of a sarcomeric
protein (most likely titin [7]). b
A significant relation was found
between in vivo LV end-
diastolic pressure and cardio-
myocyte stiffness, indicating
that the in vivo diastolic dys-
function in HFNEF patients is at
least partly due to an intrinsic
defect of the myofilaments. c
Illustrates that the increased
myofilament passive stiffness
would impair diastolic function
of the heart of HFNEF patients
compared to controls, while the
force-generating capacity of the
myofilaments during systole
may be somewhat lower com-
pared to controls. d PKA treat-
ment corrected myofilament
diastolic dysfunction to values
observed in controls
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hemodynamic data are collected at the time of biopsy
procurement and samples are directly frozen in liquid
nitrogen, which will fix phosphorylation status of the
myofilament proteome. This allowed us to show that the
high intrinsic passive stiffness of the myofilaments corre-
lated well with LV end-diastolic pressure (Fig. 3b) [11],
which indicates that increased passive myofilament stiff-
ness is an important contributor to diastolic dysfunction in
HFNEF patients. Compared to control cells from individ-
uals with normal LVEF and normal LV end-diastolic
pressure, force development by the myofilaments was
higher at low “diastolic” Ca2+ concentrations and slightly
lower at higher “systolic” Ca2+ concentrations in HFNEF as
illustrated in the force-calcium relations in Fig. 3c. Treat-
ment with exogenous PKA significantly reduced passive
stiffness and abolished the difference in myofilament
passive force between HFNEF and control cells (Fig. 3a,
d), while force development at systolic Ca2+ concentrations
remained somewhat lower in HFNEF compared to the
control group.
Correction of passive stiffness in HFNEF with PKA
indicated that the myofilament dysfunction is caused by
protein hypophosphorylation. As mentioned above, the
main protein involved in myofilament stiffness it the giant
sarcomeric protein titin. Previous studies have shown that
titin is a target of PKA, PKG, and PKC [34, 41, 75].
Phosphorylation by PKA and PKG have been shown to
reduce passive stiffness [41, 75], while PKCα treatment
increased passive stiffness in mouse and pig myocardium
[34]. In addition to reduced cTnI and cMyBP-C phosphor-
ylation, end-stage failing human hearts showed a deficit in
titin phosphorylation compared to non-failing donor hearts
[40]. A study in catheter biopsies from HFNEF and HFREF
patients indicated relative hypophosphorylation of the stiff
N2B isoform compared to control samples [12]. These data
support the hypothesis that hypophosphorylated titin causes
increased passive stiffness in cardiac disease. Until present,
no evidence for a detrimental effect of PKC-mediated titin
phosphorylation has been found in human cardiac samples.
Opposite to the expected increase in passive stiffness, PKC
treatment of end-stage failing cardiomyocytes slightly
reduced passive force [38]. However, the exact modulating
role of PKC-mediated titin phosphorylation on passive
stiffness in human myocardium should be more carefully
assessed in cardiac tissue which is obtained after different
stimuli, e.g., after alpha-adrenergic receptor stimulation,
which is known to activate downstream PKC.
Phosphorylation deficits of titin may be counterbalanced
by adaptations in titin isoform composition possibly aimed
to lower passive myofibrillar stiffness [14, 35]. Titin
isoform switching has been demonstrated in end-stage
failing myocardium: a shift from the stiff N2B isoform to
the compliant N2BA isoform coincided with lower passive
stiffness [46, 50] and may rescue diastolic dysfunction.
Alternatively, a maladaptive shift towards the stiff N2B
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Fig. 4 Comparison of passive force measurements in cells isolated
from cardiac biopsies taken during cardiac catheterization (control,
HFNEF, and HFREF) and from heart tissue obtained during heart
transplantation surgery (donor, IDCM, and ISHD) illustrates high
passive stiffness in HFNEF and HFREF patients, similar values in
control and donor hearts, and low passive force in idiopathic and
ischemic end-stage failing cardiomyopathy
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Fig 5 Comparison of heart failure patients with normal (HFNEF) and
reduced (HFREF) left ventricular ejection fraction which received
chronic β-blocker therapy +BB compared to patients untreated with
β-blockers −BB showed higher passive stiffness in HFNEF patients
treated with β-blockers a, while the percentage of collagen volume
fraction (CVF) was significantly lower in the HFNEF patients with β-
blockers b. Passive force was higher in HFNEF compared to HFREF
patients, while CVF was higher in HFREF than in HFNEF
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isoform has been reported in human samples from patients
with aortic stenosis and LV hypertrophy [71], which would
exert a detrimental effect on diastolic function.
Figure 4 depicts passive stiffness measured in single
cells isolated from catheter biopsies and from hearts which
were obtained during heart transplantation surgery. Passive
stiffness was highest in HFNEF and HFREF patients which
were classified as relatively moderate forms of heart failure
(NYHA II to III). Passive stiffness was lowest in end-stage
failing human hearts classified as NYHA IV. Noteworthy,
passive force development in control cardiac catheter
biopsies and donor hearts are similar. The changes in
passive stiffness in patient groups compared to the control
groups may reflect altered passive stiffness during the
progression of cardiac disease, characterized by an en-
hanced passive stiffness at relatively early stages of the
disease where titin phosphorylation deficits are predomi-
nant, and lower passive stiffness in end-stage failing hearts
in which the shift to more compliant titin balances the
perturbations in titin phosphorylation.
Clinical perspectives
Large clinical trials have convincingly shown that β-
blocker therapy reduces mortality and improves LV
function in HFREF patients. In HFNEF patients, favourable
effects of β-blocker therapy on mortality and LV function
have not been convincingly demonstrated. Comparison of
patients who received β-blocker therapy and patients
untreated with β-blockers showed higher maximal force-
generating capacity of myofilament in patients with β-
blocker therapy, which may underlie improved systolic
performance [31]. However, β-blocker therapy increased
passive force in HFNEF patients (Fig. 5a), which may even
worsen diastolic dysfunction. A positive effect of the β-
blockers was observed on the extracellular matrix as the
collagen volume fraction was significantly lower in HFNEF
with β-blockers (Fig. 5b). The opposite effects of β-blocker
therapy on two important determinants of cardiac diastolic
function may partly explain the inconsistent results of β-
blocker trials in HFNEF patients. Moreover, although
collagen deposition may underlie diastolic dysfunction,
within the physiologic sarcomere lengths, stiffness is
largely determined by titin. In a recent study, Chung and
Granzier [19] have shown that titin is the dominant
contributor to LV passive pressure within physiological
volumes, while the extracellular matrix exerts a dominant
effect on LV pressure at larger volumes. As diastolic
dysfunction is present in both HFNEF and HFREF patients
and is also a major problem in the growing population of
patients with diabetic cardiomyopathy [64], it is of great
relevance to design a targeted treatment to titin-mediated
passive stiffness. Benefits of therapy targeted at myofila-
ment function may depend on the stage of cardiac disease.
In pigs, β-blocker therapy directly initiated after a
myocardial infarction reversed the increased myofilament
Ca2+-sensitivity to values observed in sham animals and
significantly reduced passive stiffness in infarct animals
[24]. The latter observations are in contrast with the data
from our human studies, which showed an increase in
passive force in β-blocker treated HFNEF patients (Fig. 5a)
and a minor increase in myofilament Ca2+-sensitivity (not
shown) [31]. Although there may be species differences,
these conflicting data may also be explained by timing at
which therapy is initiated. Longitudinal studies in large
animal models [45, 74] are warranted to disentangle
adaptive from maladaptive myofilament protein changes
in the initiation and progression of diastolic dysfunction in
heart failure.
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